Severity of neurodegeneration correlates with compromise of iron metabolism in mice with iron regulatory protein deficiencies

Annals of the New York Academy of Sciences

Volumn 1012, Issue , 2004, Pages 65-83

  Smith, Sophia R ^a   Cooperman, Sharon ^a   Lavaute, Tim ^a,e   Tresser, Nancy ^f   Ghosh, Manik ^a   Meyron Holtz, Esther ^a   Land, William ^a   Ollivierre, Hayden ^a   Jortner, Bernard ^b   Switzer III, Robert ^c   Messing, Albee ^d   Rouault, Tracey A ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

^c NeuroScience Associates   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

^e UNIVERSITY OF WISCONSIN MADISON   (United States)

^f NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Axonopathy; Ferritin; Iron; IRP; Neurodegeneration; Substantia nigra

Indexed keywords

FERRIC ION; FERRITIN; IRON REGULATORY FACTOR; IRON REGULATORY PROTEIN 1; IRON REGULATORY PROTEIN 2; NEUROTROPHIC FACTOR; TRANSFERRIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL VACUOLE; CONTROLLED STUDY; DISEASE SEVERITY; EMBRYO; FEMALE; GAIT DISORDER; GENE DELETION; GENETIC ENGINEERING; GENETIC TRANSCRIPTION; HETEROZYGOSITY; HOMOZYGOSITY; IRON METABOLISM; MALE; MICROGLIA; MOTOR DYSFUNCTION; MOUSE; NERVE DEGENERATION; NERVE FIBER DEGENERATION; NEUROPATHY; NONHUMAN; ONSET AGE; PERIKARYON; PROTEIN DEFECT; PROTEIN EXPRESSION; SUBSTANTIA NIGRA; WHITE MATTER;

ANIMALIA; MAMMALIA;

EID: 11144353669     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1306.006     Document Type: Article

References (23)

1. PONTING, C.P. 2001. Domain homologues of dopamine beta-hydroxylase and ferric reductase: roles for iron metabolism in neurodegenerative disorders? Hum. Mol. Genet. 10: 1853-1858.
2. CONNOR, J.R., G. PAVLICK, D. KARLI et al. 1995. A histochemical study of iron-positive cells in the developing rat brain. J. Comp. Neurol. 355: 111-123.
3. HILL, J.M. & R.C. SWITZER III. 1984. The regional distribution and cellular localization of iron in the rat brain. Neuroscience 11: 595-603.
4. BERG, D., M. GERLACH, M.B. YOUDIM et al. 2001. Brain iron pathways and their relevance to Parkinson's disease. J. Neurochem. 79: 225-236.
5. SMITH, M.A., P.L. HARRIS, L.M. SAYRE & G. PERRY. 1997. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc. Natl. Acad. Sci. USA 94: 9866-9868.
6. HAYFLICK, S.J. 2003. Pantothenate kinase-associated neurodegeneration (formerly Hallervorden-Spatz syndrome). J. Neurol. Sci. 207: 106-107.
7. TAKANASHI, M., H. MOCHIZUKI, K. YOKOMIZO et al. 2001. Iron accumulation in the substantia nigra of autosomal recessive juvenile parkinsonism. ARJP 7: 311-314.
8. DICKSON, D.W., W. LIN, W.K. LIU & S.H. YEN. 1999. Multiple system atrophy: a sporadic synucleinopathy. Brain Pathol. 9: 721-732.
9. WILSON, R.B. 2003. Frataxin and frataxin deficiency in Friedreich's ataxia. J. Neurol. Sci. 207: 103-105.
10. LAVAUTE, T., S. SMITH, S. COOPERMAN et al. 2001. Targeted deletion of iron regulatory protein 2 causes misregulation of iron metabolism and neurodegenerative disease in mice. Nat. Genet. 27: 209-214.
11. ROUAULT, T. & R. KLAUSNER. 1997. Regulation of iron metabolism in eukaryotes. Curr. Top. Cell. Regul. 35: 1-19.
12. SCHNEIDER, B.D. & E.A. LEIBOLD. 2000. Regulation of mammalian iron homeostasis. Curr. Opin. Clin. Nutr. Metab. Care 3: 267-273.
13. FRANCOIS, C., J. NGUYEN-LEGROS & G. PERCHERON. 1981. Topographical and cytological localization of iron in rat and monkey brains. Brain Res. 215: 317-322.
14. DE OLMOS, J.S., C.A. BELTRAMINO & S. DE OLMOS DE LORENZO. 1994. Use of an amino-cupric-silver technique for the detection of early and semiacute neuronal degeneration caused by neurotoxicants, hypoxia, and physical trauma. Neurotoxicol. Teratol. 16: 545-561.
15. GRABILL, C., A.C. SILVA, S.S. SMITH et al. 2003. MRI detection of ferritin iron overload and associated neuronal pathology in iron regulatory protein-2 knockout mice. Brain Res. 971: 95-106.
16. MARTIN, L.J., N.A. AL-ABDULLA, A.M. BRAMBRINK et al. 1998. Neurodegeneration in excitotoxicity, global cerebral ischemia, and target deprivation: a perspective on the contributions of apoptosis and necrosis. Brain Res. Bull. 46: 281-309.
17. ARMSTRONG, R.A., P.L. LANTOS & N.J. CAIRNS. 2002. Spatial patterns of the vacuolation in subcortical white matter in sporadic Creutzfeldt-Jakob disease (sCJD). Clin. Neuropathol. 21: 284-288.
18. HE, L., X.Y. LU, A.F. JOLLY et al. 2003. Spongiform degeneration in mahoganoid mutant mice. Science 299: 710-712.
19. ROUAULT, T.A. 2001. Iron on the brain. Nat. Genet. 28: 299-300.
20. KAUR, D., F. YANTIRI, S. RAJAGOPALAN et al. 2003. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 37: 899-909.
21. LOPACHIN, R.M., C.D. BALABAN & J.F. ROSS. 2003. Acrylamide axonopathy revisited. Toxicol. Appl. Pharmacol. 188: 135-153.
22. RAFF, M.C., A.V. WHITMORE & J.T. FINN. 2002. Axonal self-destruction and neurodegeneration. Science 296: 868-871.
23. GILL, S.S., N.K. PATEL, G.R. HOTTON et al. 2003. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med. 9: 589-595.